Multi-omics in systemic sclerosis with emphasis on extracellular vesicles
Abstract
Systemic sclerosis (SSc) is a rare and complex autoimmune disease of unknown aetiology. Although vasculopathy, immune dysregulation, and fibrosis are recognized as key features of the disease, the mechanisms and factors driving their onset and progression remain incompletely understood. In recent years, advances in omics technologies including genomics, epigenomics, transcriptomics, proteomics, and metabolomics have facilitated the identification of dysregulated molecular pathways and potential biomarkers, providing deeper insights into SSc pathophysiology. In this review, we first discuss the results of omics studies in plasma and in specific organs, particularly the lungs and skin, which are the organs primarily affected by SSc. The role of the identified molecules is discussed in relation to the various dysregulated pathways in the disease. We then focus on omics studies of extracellular vesicles (EVs). Despite the limited number of studies, the systemic nature of SSc makes it crucial to determine whether EVs can transport molecular components, including small non-coding RNAs, proteins and metabolites, that contribute to disease exacerbation. The omics data provide valuable information about the molecules that are transported by EVs and the underlying mechanisms that drive disease progression, potentially enabling the discovery of new biomarkers for improved diagnosis and prognosis. We also discuss the advantages of using EVs rather than conventional biomarkers in SSc, as well as the challenges and recommendations for omics analysis.
Related
- Systemic IgG responses to Leishmania braziliensis–derived extracellular vesicles vary across clinical forms of American tegumentary leishmaniasis and associate with early therapeutic outcome
- Development of a multi-organ single-cell atlas of systemic sclerosis reveals shared and tissue-specific pathogenic pathways.
- ICAM-5: A marker for neuronally derived extracellular vesicles
- Mitochondrial and bioenergetic processes are enriched in large-but are reciprocally depleted in small extracellular vesicles
- HIF2α-Regulated Pathways Control Human Extravillous Trophoblast Functions by Modulating Cell-to-Cell Communication Through Extracellular Vesicles
BibTeX
@article{ibarissen2026multiomics,
title = {{Multi-omics in systemic sclerosis with emphasis on extracellular vesicles}},
author = {Dalia Ibarissen and Alexandre Maria and Guilhem Graveron and Christian Jorgensen and Pauline Rozier and Danièle Noël},
journal = {Molecular Medicine},
year = {2026},
month = sep,
doi = {10.1186/s10020-026-01642-x},
url = {https://inserm.hal.science/inserm-05850573v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multi-omics in systemic sclerosis with emphasis on extracellular vesicles
AU - Dalia Ibarissen
AU - Alexandre Maria
AU - Guilhem Graveron
AU - Christian Jorgensen
AU - Pauline Rozier
AU - Danièle Noël
PY - 2026
DA - 2026/09/21
JO - Molecular Medicine
DO - 10.1186/s10020-026-01642-x
UR - https://inserm.hal.science/inserm-05850573v1
AB - Systemic sclerosis (SSc) is a rare and complex autoimmune disease of unknown aetiology. Although vasculopathy, immune dysregulation, and fibrosis are recognized as key features of the disease, the mechanisms and factors driving their onset and progression remain incompletely understood. In recent years, advances in omics technologies including genomics, epigenomics, transcriptomics, proteomics, and metabolomics have facilitated the identification of dysregulated molecular pathways and potential biomarkers, providing deeper insights into SSc pathophysiology. In this review, we first discuss the results of omics studies in plasma and in specific organs, particularly the lungs and skin, which are the organs primarily affected by SSc. The role of the identified molecules is discussed in relation to the various dysregulated pathways in the disease. We then focus on omics studies of extracellular vesicles (EVs). Despite the limited number of studies, the systemic nature of SSc makes it crucial to determine whether EVs can transport molecular components, including small non-coding RNAs, proteins and metabolites, that contribute to disease exacerbation. The omics data provide valuable information about the molecules that are transported by EVs and the underlying mechanisms that drive disease progression, potentially enabling the discovery of new biomarkers for improved diagnosis and prognosis. We also discuss the advantages of using EVs rather than conventional biomarkers in SSc, as well as the challenges and recommendations for omics analysis.
SN - 1076-1551
SN - 1528-3658
ER -